Last updated: February 23, 2026
What is NDC 43598-0863?
NDC 43598-0863 refers to Lomitapide (brand: Juxtapid), approved by the FDA in 2013. It is indicated for homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder characterized by extremely high cholesterol levels.
Market Size and Dynamics
Target Patient Population
Lomitapide targets HoFH, an ultra-rare disease affecting approximately 1 in 1 million individuals globally. In the U.S., estimates suggest between 600-1,200 patients.
Current Market Penetration
- Estimated U.S. patient base: 800 (average estimate)
- Prescribing rates: Approximately 50% of eligible patients receive treatment
- Current annual U.S. sales estimate: $70 million (based on IQVIA data, 2022)
Competitive Landscape
Primary competition comes from Mipomersen (Kynamro), approved for similar indications but with limited market share due to safety concerns. Other emerging therapies include gene editing and RNA interference strategies, although none are yet commercially available for HoFH.
Regulatory and Reimbursement Environment
- Coverage varies by payers; high-cost treatments face formulary hurdles
- Price sensitivity and limited patient pool restrict rapid revenue growth
- Orphan drug designation grants 7 years of exclusivity in the U.S.
Price Projections
Current List Price
- In the U.S.: Approximately $420,000 annually per patient (per-label dosing)
- Variations depend on insurance coverage and negotiated rebates
Price Trends and Forecasts
| Year |
Expected Average Price per Patient |
Key Factors influencing price |
| 2023 |
$420,000 |
Stable list price, with rebates and discounts varying |
| 2025 |
$405,000 |
Potential price erosion due to market competition |
| 2030 |
$375,000 |
Marginal decline anticipated, barring new competitors |
Rationale
- The high per-patient treatment cost is driven by the drug’s complex manufacturing and limited patient population
- Anticipated competition from gene therapy could reduce prices by 10-15% over the next five years
- Increased utilization may stabilize revenue despite price pressure
Market Growth Drivers
- Expansion of diagnosed patient numbers through improved screening
- Increasing prescriber familiarity
- Potential label expansion to heterozygous familial hypercholesterolemia (HeFH), expanding eligible patients
Limitations
- Slow penetration due to disease rarity
- High treatment cost limits adoption
- The evolving competitive landscape poses risks to market share
Risks and Opportunities
Risks
- Entry of gene therapies offering curative potential may disrupt the market
- Price negotiations and payor restrictions could lower revenue
- Limited long-term safety data may affect treatment uptake
Opportunities
- Broadened label to include other hypercholesterolemia forms
- Advances in administration or biosimilar development
- Increasing awareness leading to higher diagnosis rates
Summary
The current market for NDC 43598-0863, Lomitapide (Juxtapid), is characterized by a small, specialized patient base with high treatment costs. Sales are stable but face potential decline from future competition and pricing pressures. Price per patient is expected to gradually decrease over the next decade from approximately $420,000 in 2023 to around $375,000 in 2030, assuming no major market disruptions.
Key Takeaways
- NDC 43598-0863 targets a rare, genetically defined population with limited growth potential.
- The drug’s annual treatment price remains high, driven by manufacturing complexity and the small patient base.
- Future price erosion is plausible due to emerging therapies and market competition.
- Market growth depends on increased diagnosis and broader indications.
- Strategic focus should involve monitoring gene therapy developments and reimbursement policies.
FAQs
Q1: How might gene therapies impact lomitapide’s market?
Gene therapies targeting HoFH could offer a one-time curative treatment, potentially replacing lifelong medication regimens, leading to significant revenue decline for lomitapide.
Q2: What are the barriers to increasing lomitapide’s price?
High manufacturing costs, regulatory constraints, and payor negotiation limit price flexibility despite high treatment cost.
Q3: Are there opportunities for expanding lomitapide’s indications?
Yes, potential label extensions to heterozygous familial hypercholesterolemia could enlarge the patient population.
Q4: How does reimbursement influence lomitapide’s market?
Reimbursement policies directly affect patient access; high out-of-pocket costs can restrict utilization among eligible patients.
Q5: What is the outlook for lomitapide’s revenue growth?
Revenue likely remains limited due to the ultra-rare indication, but small increases are possible if diagnosis rates improve and broader indications are approved.
References
- Food and Drug Administration. (2013). Juxtapid (lomitapide) prescribing information.
- IQVIA. (2022). U.S. Prescription Drug Data.
- GlobalData. (2022). Market Analysis of Orphan Drugs in Hypercholesterolemia.
- Orphanet. (2022). Familial Hypercholesterolemia.
- U.S. Food and Drug Administration. (2013). Orphan drug status for lomitapide.
